Table 3.

Response According to Previous Therapy in Patients with Chronic-Phase CML.

Variable	All Patients		Patients with Resistance or Unacceptable Side Effects		T315I Mutation
	no.	% (95% CI)	no.	% (95% CI)	no.	% (95% CI)
One previous approved tyrosine kinase inhibitor*	19†		4		12
Major cytogenetic response‡		79 (54–94)		50 (7–93)		83 (52–98)
Complete cytogenetic response		74 (49–91)		50 (7–93)		75 (43–95)
Major molecular response		47 (24–71)		0		67 (35–90)
Two previous approved tyrosine kinase inhibitors*	98		68		30
Major cytogenetic response‡		67 (57–76)		63 (51–75)		77 (58–90)
Complete cytogenetic response		56 (46–66)		49 (36–61)		73 (54–88)
Major molecular response		36 (26–46)		28 (18–40)		53 (34–72)
Three previous approved tyrosine kinase inhibitors*	141		119		22
Major cytogenetic response‡		45 (37–54)		44 (35–53)		55 (32–76)
Complete cytogenetic response		39 (31–48)		37 (28–46)		50 (28–72)
Major molecular response		33 (26–42)		29 (21–38)		55 (32–76)
Four previous approved tyrosine kinase inhibitors*	12		12
Major cytogenetic response‡		58 (28–85)		58 (28–85)		—
Complete cytogenetic response		25 (5–57)		25 (5–57)		—
Major molecular response		8 (0.2–38)		8 (0.2–38)		—

^*Patients may have received other, nonapproved tyrosine kinase inhibitors.

^† This category includes the three patients who were not assigned to a cohort; they were T315I-negative at baseline and had not previously received dasatinib or nilotinib, but they had received imatinib.

^‡ A major cytogenic response consists of a partial cytogenic response plus a complete cytogenic response.